Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia
Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noel, Elisabeth Luthringer, Sandra Werner, Joseph Reilly, Jean Yves Schaffhauser, Jonathan Rabinowitz, Mark Weiser, Remy Luthringer
Research output: Contribution to journal › Article › peer-review
84Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia'. Together they form a unique fingerprint.